SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending amid a broader crypto market dip, leading to community discussions about potential bottom levels and future rallies, with some traders anticipating a recovery in October. The conversation includes speculation about market manipulation and the influence of macroeconomic factors such as government shutdowns and potential shifts in investment from crypto to marijuana stocks. Despite the current volatility, some community members remain optimistic, pointing to long-term growth potential and the possibility of new all-time highs.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending amid a broader crypto sell-off, with community members debating the causes, including potential government shutdowns and macroeconomic factors. Some traders are pointing to technical indicators and anticipating further dips, while others view the current prices as a buying opportunity before a potential Q4 uptrend. The conversation also involves speculation around market manipulation and the influence of key figures like Tom Lee.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy (MSTR) is trending downwards, with community members pointing to its correlation with Bitcoin's recent struggles and potential dilution. Bears are celebrating the price action, while bulls are hoping for a turnaround and discussing key support levels. Chatter suggests traders are weighing whether to treat MSTR as a leveraged Bitcoin play or if the volatility risk is too high.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Shares of Cipher Mining are volatile as the community debates the implications of a newly announced deal and associated convertible note offering; some express concerns about potential dilution, while others view the deal with Google-backed Fluidstack as a major win for the company's expansion into AI data centers. Community members are actively discussing the long-term potential versus near-term risks, with some calling it a buying opportunity amid the pullback, while others remain cautious.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid discussions about market manipulation and potential impacts from broader economic factors, as community members debate the possibility of further price corrections or an imminent bounce. Sentiment is mixed, with some traders buying the dip in anticipation of future gains while others express frustration with the price action and question the timing of potential catalysts like ETFs. News about Ripple partnerships and the potential for asset tokenization may also be influencing the conversation.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CRWV is experiencing significant intraday volatility, driven by a mix of broader market concerns and company-specific news. The community is actively debating potential support levels and the impact of a lock-up period, while also analyzing the implications of the company's relationship with key players in the AI sector. Despite positive news catalysts, some traders express frustration with the stock's price action, citing manipulation and external market pressures.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARA is trending amidst Bitcoin's volatility and fluctuating miner performance, sparking debate about its management and debt. Community discussions revolve around whether it can sustain gains, with some citing dilution concerns while others point to potential short squeezes. Positive catalysts include Trump's pro-crypto stance, but this is weighed against broader discussions of AI, HPC, and sector comparisons.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow With Knife ($CAW.X) is trending as the community highlights its multichain functionality across Solana, BSC, Cronos, and Ethereum, with a built-in burn mechanism. Community members are emphasizing its organic growth, strong community, and the deflationary nature of the token. Bullish sentiment is high as some users encourage buying the dip.

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

SciSparc Ltd

Scisparc Ltd

SPRC is trending due to community discussion around a quantum computing initiative for AI drug discovery, with retail traders debating its potential and the possibility of a short squeeze. Bullish investors are optimistic about the company's technology and are targeting a short burn, while bears point to potential dilution and low profitability. The stock's volatile price action and high short interest are also fueling the conversation.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco's stock is trending amid discussions about its high valuation and upcoming earnings report, with some traders anticipating a potential drop. Community debates whether the stock is overvalued compared to peers, while others cite its strong membership model and defensive qualities. Tariffs and consumer spending habits are also being closely monitored for their potential impact on the company's performance.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Ardelyx Inc. (ARDX) jumped 16% higher on Tuesday morning after multiple brokerages upped their price targets on the stock following an upbeat second-quarter earnings report and management changes.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARDX">ARDX</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels. According to Stocktwits data, retail chatter around ARDX jumped 1738% over the past 24 hours, as of Tuesday morning.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_05_at_10_56_25_AM_png_178eba0feb.webp" alt="ARDX's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 5, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>ARDX's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user heaped praises on the management.<stembedurl>https://stocktwits.com/hpf6637/message/623772356</stembedurl>Another user expressed hopes for further price target increases into the high teens.<stembedurl>https://stocktwits.com/Paul_Volcker/message/623769111</stembedurl>Ardelyx on Monday announced changes to its executive leadership team, including the appointment of Edward Conner as Chief Medical Officer and the exit of CFO Justin Renz. The appointments came on the heels of the company reporting $97.7 million in total revenue, reflecting 33% growth year-over-year, and above an analyst estimate of $81.08 million.Ibsrela, the company’s prescription medicine used in adults to treat irritable bowel syndrome with constipation, generated its highest-ever net sales revenue of $65 million in the quarter. Meanwhile, Xphozah, a prescription medicine used to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy, brought in $25 million in the quarter.The company also raised its Ibsrela net sales revenue expectations to $250 million to $260 million for the full year 2025. Net loss per share came in at $0.08, compared to a loss of $0.07 per share reported in the corresponding quarter of 2024, but below a loss per share of $0.14 expected by analysts.Multiple analysts subsequently hiked their price target on the stock on Tuesday morning. Wedbush raised its price target on Ardelyx to $14 from $13 and kept an ‘Outperform’ rating on the shares. The firm noted that Ardelyx posted a solid performance in Q2, driven by Ibsrela strength.Raymond James, meanwhile, raised the firm's price target on Ardelyx to $12 from $11 and kept an ‘Outperform’ rating on the shares. ARDX stock is up by 1% this year but down by about 12% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shareholders-reportedly-sue-ev-giant-ceo-elon-musk-over-robotaxi-claims/chrLMCtRd21">Tesla Shareholders Reportedly Sue EV Giant, CEO Elon Musk Over Robotaxi Claims: Retail’s In Wait-And-Watch Mode</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming

Wedbush raised its price target on Ardelyx to $14 from $13 and kept an ‘Outperform’ rating on the shares.

Equity

Wedbush raised its price target on Ardelyx to $14 from $13 and kept an ‘Outperform’ rating on the shares.


Ardelyx (ARDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Ardelyx (ARDX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of +38.46% and +15.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shares of Ardelyx, Inc. (ARDX) traded 22% lower on Friday afternoon after Citi lowered its price target on the stock following its recent first-quarter earnings report.Citi reduced its price target on Ardelyx to $10 from $11 while keeping a ‘Buy’ rating. The new price target, however, represents an 83% upside to the stock’s closing price on Thursday.Raymond James also downgraded Ardelyx to ‘Outperform’ from ‘Strong Buy’, and slashed its price target to $11 from $13.The firm said that recent net sales weakness has created added uncertainty regarding the long-term growth of the Ibsrela and Xphozah franchises.Despite the downgrade, Raymond James remains bullish on Ardelyx, citing its strong execution track record.Ardelyx <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-reports-first-quarter-2025-financial-results-and">reported</a> Q1 total revenue of $74.1 million on Thursday, marking &nbsp;61% growth year-over-year and reflecting increased net product sales and licensing revenue. However, as per Finchat data, this was below an analyst estimate of $79.44 million.U.S. net product sales revenue of Ibsrela, the company’s prescription medication for treating Irritable Bowel Syndrome with Constipation, was $44.4 million, compared to $28.4 million during the same period of 2024.The U.S. net product sales revenue of Xphozah, used as an add-on therapy to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis, was $23.4 million, compared to $15.2 million during the same period in 2024.Net loss per share for the quarter was $0.17, compared to a loss of $0.11 per share in the same quarter of 2024, and broader than an estimated loss of $0.07.On Stocktwits, retail sentiment around ARDX remained in the ‘extremely bullish’ territory over the past 24 hours while message volume rose to ‘extremely high’ from ‘high’.<figure class="image"><img style="aspect-ratio:626/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_02_at_1_56_59_PM_png_99a9fe03a2.webp" alt="ARDX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 2, 2025 | Source: Stocktwits" width="626" height="59"><figcaption>ARDX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 2, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> is down by over 17% this year and nearly 38% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/volkswagen-core-brand-group-operating-profit-drops-q1/chLUkWFRb0z">Volkswagen Core Brand Group Operating Profit Drops In Q1: But Retail’s Not Rattled</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Ardelyx Stock Gets Multiple Price Target Cuts After Disappointing Q1 Earnings: But Retail’s Optimistic

Raymond James said that recent net sales weakness has created added uncertainty regarding the long-term growth of the Ibsrela and Xphozah franchises. 

Shares of biopharma company Ardelyx, Inc. (ARDX) edged up about 0.5% in after-hours trading on Thursday after closing lower during the regular session as investors processed its quarterly earnings and drug sales projections.Ardelyx swung to a fourth-quarter (Q4) net income of $0.02 per diluted share from a loss of $0.12 a year earlier, surpassing analyst expectations of breakeven.&nbsp;Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.Total revenue for the year ended Dec. 31, 2024, was $333.6 million, compared to $124.5 million a year earlier.Ibsrela, its treatment for irritable bowel syndrome with constipation, generated $53.8 million in Q4 net product sales revenue, reflecting about 32% growth from Q3.&nbsp;Full-year 2024 sales reached $158.3 million, and the company expects U.S. net product sales for 2025 to range between $240 million and $250 million.&nbsp;Ardelyx projects Ibsrela to achieve over 10% market share at peak and exceed $1 billion in annual U.S. revenue before its patent expires in 2029.Xphozah, used to manage serum phosphorus levels in adults with chronic kidney disease on dialysis, recorded $57.2 million in Q4 net product sales.In 2024, Xphozah's first full year of commercialization saw U.S. sales hit $160.9 million. The company estimates that peak annual U.S. sales will reach $750 million before its patent expires.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ARDX_sentiment_and_message_volume_Feb_20_c5531a04cb.png" alt="ARDX sentiment and message volume Feb 20.png">On Stocktwits, sentiment for ARDX surged deeper into the 'extremely bullish' zone, with message volume spiking 240% in 24 hours.&nbsp;One user highlighted IBSRELA's trajectory toward blockbuster drug status, while another reinforced faith in the company's fundamentals.<stembedurl>https://stocktwits.com/Food4Thought/message/605066169</stembedurl><stembedurl>https://stocktwits.com/Newtothis321/message/604963175</stembedurl>Ardelyx ended 2024 with $250.1 million in cash, cash equivalents, and short-term investments, up from $184.3 million a year earlier.&nbsp;The stock has gained over 13% year-to-date, though short interest has increased from 10% at the start of 2025 to about 11.2% last week, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism

Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.

Ardelyx Beats Q3 Sales Estimates, Shares Climb

Ardelyx reported its third-quarter results after Thursday's closing bell. Here's a look at the details from the report:
read more...

Ardelyx's Earnings Outlook

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. (Ardelyx or the Company) (NASDAQ: ARDX) and reminds investors of the October 15...

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

Stocktwits

) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

ARDX
Ardelyx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARDX News

ARDX Ardelyx Inc